BACHEM RAISES CHF 583.5 MILLION THROUGH CAPITAL INCREASE Dienstag, 19. Oktober 2021 - 07:02
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX
BACHEM RAISES CHF 583.5 MILLION THROUGH CAPITAL INCREASE TO ACCELERATE THE ONGOING CAPACITY EXPANSION
- Following the Extraordinary General Meeting on October 15, 2021, Bachem has successfully raised approximately CHF 584 million through a capital increase.
- The new shares are expected to be listed and admitted to trading on the SIX Swiss Exchange on October 20, 2021.
- The capital increase will allow Bachem to finance investments in capacity expansion.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Media: media[at]bachem.com
Investors: ir[at]bachem.com